NKF-K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis2003; 44(suppl 3).
2.
Naveh-ManyT., RahaminovR., SilverJ.Parathyroid cell proliferation in normal and chronic renal failure rats: the effect of calcium, phosphate and vitamin D. J Clin Invest1995; 96: 327–33.
3.
LlachF., MassryS.G.On the mechanism of secondary hyperparathyroidism in moderate renal failure. J Clin End Met1985; 61: 601–6.
4.
SlatopolskyE., WeertsC., Lopez-HilkerS.Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med1986; 315: 157–61.
5.
BrancaccioD., ZoccaliC.The continuous challenge of cardiovascular and bone disease in uremic patients: clinical consequences of hyperphosphatemia and advanced therapeutic approaches. J Nephrol2006; 19: 12–20.
6.
SchoenfeldP., HenryR., LairdN.Assesment of nutritional status of the NCDS population. Kidney Int1980; 23: 580–8.
7.
LotzM., ZismanE., BartterF.C.Evidence for a phosphorus-depletion syndrome in man. N Engl J Med1968; 278: 409–15.
8.
ParkinsonI.S., FeestT.G., WardM.K.Fracturing dialysis osteodystrophy and dialysis encephalopathy: an epidemiological survey. Lancet1979; 1: 406–8.
9.
RamirezJ.A., EmmettM., WhiteM.G.The adsorption of dietary phosphorus and calcium in hemodialysis patients. Kidney Int1986; 30: 753–9.
10.
SheikhM.S., MaguireJ.A., EmmettM.Reduction of dietary phosphorus absorption by phosphate binders: A theoretical, in vitro and in vivo study. J Clin Invest1989; 83: 66–73.
11.
RitzE., HergesellO.Oral phosphate binders without aluminium and calcium a pipe dream?Nephrol Dial transplant1996; 11: 766–8.
12.
JenkinsD.A., GouldesbroughD., MithG.D.Can low-dosage aluminum hydroxide control the plasma phosphate without bone toxicity?Nephrol Dial Transplant1989; 4: 51–6.
13.
ParfittA.M.Soft tissue calcification in uremia. Arch Intern Med1969; 124: 544–55.
14.
GoodmanW.G., GoldinJ., KuizonB.D., YoonC., GalesB., SiderD., ElashoffR., SaluskyI.B.Coronary-artery calcification in young adults with end-stage renal disease who undergo dialysis. N Engl J Med2000; 342: 1478–83.
15.
GuerinA.P., LondonG.M., MarchaisS., MetivierF.Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant2000; 15: 1014–21.
16.
BlacherJ., GuerinA.P., PannierB., MarchaisS., LondonG.M.Arterial calcifications, arterial stiffness and cardiovascular risk in end stage renal disease. Hypertension2001; 38: 938–42.
17.
GaneshSK, StackA.G., LevinN.W., Hulbert-ShearonT., PortF.K.Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. Am Soc Nephrol2001; 12: 2131–8.
18.
SlininY., FoleyR.N., CollinsA.J.Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol2005; 16: 1788–93.
